The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology
The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vacc...
Uloženo v:
| Vydáno v: | Epidemiology (Cambridge, Mass.) Ročník 31; číslo 1; s. 43 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2020
|
| Témata: | |
| ISSN: | 1531-5487, 1531-5487 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines.
We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE.
We identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities.
Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies. |
|---|---|
| AbstractList | The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines.
We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE.
We identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities.
Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies. The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines.BACKGROUNDThe test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines.We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE.METHODSWe conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE.We identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities.RESULTSWe identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities.Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies.CONCLUSIONSOur review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies. |
| Author | Chua, Huiying Lewnard, Joseph A Sullivan, Sheena G Blyth, Christopher C Cowling, Benjamin J Feng, Shuo Lipsitch, Marc |
| Author_xml | – sequence: 1 givenname: Huiying surname: Chua fullname: Chua, Huiying organization: From the World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 2 givenname: Shuo surname: Feng fullname: Feng, Shuo organization: From the World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 3 givenname: Joseph A surname: Lewnard fullname: Lewnard, Joseph A organization: Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA – sequence: 4 givenname: Sheena G surname: Sullivan fullname: Sullivan, Sheena G organization: Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia – sequence: 5 givenname: Christopher C surname: Blyth fullname: Blyth, Christopher C organization: Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia – sequence: 6 givenname: Marc surname: Lipsitch fullname: Lipsitch, Marc organization: Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, MA – sequence: 7 givenname: Benjamin J surname: Cowling fullname: Cowling, Benjamin J organization: From the World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31609860$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URB_wDxDykUuKndQvblUJD6kVErRcI8dZt0GJXeK0qP-eVIDUvcwevh3N7BD1nHeA0DUlY0qUuEsf0jE5GUopP0MDyhIasYkUvZO9j4YhfHaMSCi7QP2EcqIkJwNklxvAqwDYW7yE0EYO1rot94Bn3rWNrwJuPV54V7a-wR_amNIBTq0Fc6QchHCPp_j9EFqou0OD32BfwvfRbwHtxhe-8uvDJTq3ugpw9acjtHpMl7PnaP769DKbziMz6eJHxlpj8pzbROfU2sQqKwQFLou4UEZKxvI4l0JK1RUhRSy5ZoZpzbWyhlMWj9Dtr--28V-7rk9Wl8FAVWkHfheyOCFMKMFI0qE3f-gur6HItk1Z6-aQ_f8m_gEOY2lV |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2024_04_044 crossref_primary_10_1371_journal_pone_0300198 crossref_primary_10_1016_S2352_4642_23_00225_0 crossref_primary_10_1097_INF_0000000000003367 crossref_primary_10_1016_j_vaccine_2022_10_034 crossref_primary_10_1093_milmed_usac436 crossref_primary_10_1126_sciadv_adu8678 crossref_primary_10_1016_j_jinf_2023_05_020 crossref_primary_10_1038_s41541_023_00716_9 crossref_primary_10_1016_j_vaccine_2024_05_002 crossref_primary_10_1038_s41467_025_62358_w crossref_primary_10_1001_jama_2020_19328 crossref_primary_10_1111_irv_13087 crossref_primary_10_3390_v14102086 crossref_primary_10_1080_01621459_2023_2220935 crossref_primary_10_1016_j_virusres_2022_199033 crossref_primary_10_1038_s41467_025_59768_1 crossref_primary_10_17269_s41997_021_00554_z crossref_primary_10_1093_aje_kwae288 crossref_primary_10_2196_52047 crossref_primary_10_1016_S2214_109X_25_00056_7 crossref_primary_10_1056_NEJMoa2110362 crossref_primary_10_1542_peds_2024_066393 crossref_primary_10_1111_irv_12939 crossref_primary_10_3389_fpubh_2023_1195908 crossref_primary_10_1001_jamanetworkopen_2025_3376 crossref_primary_10_1097_EDE_0000000000001708 crossref_primary_10_1001_jama_2024_5633 crossref_primary_10_1016_j_vaccine_2023_05_028 crossref_primary_10_1093_infdis_jiaf451 crossref_primary_10_1001_jamanetworkopen_2025_12763 crossref_primary_10_1093_infdis_jiae510 crossref_primary_10_1093_cid_ciaa1453 crossref_primary_10_1093_infdis_jiae597 crossref_primary_10_1007_s40265_024_02083_8 crossref_primary_10_1136_bmj_2022_072065 crossref_primary_10_1016_j_lanepe_2024_101007 crossref_primary_10_1016_S0140_6736_22_00982_5 crossref_primary_10_1056_NEJMoa2202826 crossref_primary_10_1016_j_ijid_2024_107310 crossref_primary_10_1038_s41577_021_00662_4 crossref_primary_10_1136_bjsports_2022_105734 crossref_primary_10_1016_j_ijid_2022_11_035 crossref_primary_10_1016_j_ymthe_2024_12_008 crossref_primary_10_1093_aje_kwae303 crossref_primary_10_1002_sim_8488 crossref_primary_10_1093_cid_ciaf093 crossref_primary_10_1001_jama_2022_2068 crossref_primary_10_1093_ije_dyab172 crossref_primary_10_1016_j_vaccine_2024_01_068 crossref_primary_10_1126_science_abe5938 crossref_primary_10_3390_vaccines10081225 crossref_primary_10_1177_13524585251340812 crossref_primary_10_1016_S1473_3099_22_00215_8 crossref_primary_10_3390_vaccines13010004 crossref_primary_10_3390_vaccines11050917 crossref_primary_10_1016_S1473_3099_22_00132_3 crossref_primary_10_1056_NEJMoa2204399 crossref_primary_10_1007_s12603_023_1891_3 crossref_primary_10_1093_cid_ciad584 crossref_primary_10_1186_s12874_023_01962_0 crossref_primary_10_1016_j_lanwpc_2022_100432 crossref_primary_10_1371_journal_pone_0276911 crossref_primary_10_1097_INF_0000000000003286 crossref_primary_10_1111_irv_12993 crossref_primary_10_1093_aje_kwae350 crossref_primary_10_1093_infdis_jiad483 crossref_primary_10_1001_jama_2022_0470 crossref_primary_10_1016_j_vaccine_2021_08_027 crossref_primary_10_7326_M21_3256 crossref_primary_10_2196_58981 crossref_primary_10_1093_cid_ciab1040 crossref_primary_10_1001_jama_2022_7493 crossref_primary_10_1056_NEJMe2113151 crossref_primary_10_1056_NEJMoa2117995 crossref_primary_10_2217_cer_2022_0069 crossref_primary_10_1093_infdis_jiab474 crossref_primary_10_1056_NEJMe2110605 crossref_primary_10_1093_aje_kwaf176 crossref_primary_10_1093_infdis_jiae220 crossref_primary_10_12688_wellcomeopenres_23653_1 crossref_primary_10_3390_vaccines12111265 crossref_primary_10_1016_S1473_3099_25_00156_2 crossref_primary_10_1371_journal_pone_0317686 crossref_primary_10_1371_journal_pone_0283715 crossref_primary_10_1016_j_jpeds_2022_09_039 crossref_primary_10_1136_archdischild_2022_324455 crossref_primary_10_1016_j_medcle_2023_06_007 crossref_primary_10_1093_aje_kwab066 crossref_primary_10_1097_EDE_0000000000001473 crossref_primary_10_1093_ofid_ofad577 crossref_primary_10_1007_s00431_025_06008_9 crossref_primary_10_1016_j_medcli_2023_06_004 crossref_primary_10_1016_j_imu_2024_101561 crossref_primary_10_1016_j_vaccine_2024_04_061 crossref_primary_10_1136_bmjopen_2021_060407 crossref_primary_10_1038_s41467_022_31839_7 crossref_primary_10_1186_s12874_024_02277_4 crossref_primary_10_3390_ijerph19074039 crossref_primary_10_3390_vaccines11010049 crossref_primary_10_1007_s00431_024_05785_z crossref_primary_10_3389_fpubh_2021_739076 crossref_primary_10_1097_EDE_0000000000001484 crossref_primary_10_3390_vaccines10122074 crossref_primary_10_1097_EDE_0000000000001366 crossref_primary_10_1016_S1473_3099_25_00382_2 crossref_primary_10_1038_s41467_022_33169_0 crossref_primary_10_1016_j_vaccine_2023_12_013 crossref_primary_10_1136_bmjph_2023_000620 crossref_primary_10_1186_s12916_022_02480_4 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/EDE.0000000000001116 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1531-5487 |
| ExternalDocumentID | 31609860 |
| Genre | Systematic Review Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: T32 AI007535 – fundername: NIGMS NIH HHS grantid: U54 GM088558 |
| GroupedDBID | --- .-D .55 .Z2 01R 0R~ 1J1 40H 4Q1 4Q2 4Q3 53G 5GY 5VS 71W 77Y 7O~ 8L- AAAAV AAAXR AACGO AAGIX AAHPQ AAIKC AAIQE AAMNW AAMOA AAMTA AANCE AAQKA AARTV AASCR AASOK AAXQO AAYEP ABASU ABBHK ABBUW ABDIG ABJNI ABPLY ABTLG ABVCZ ABXSQ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFO ACGFS ACHIC ACHQT ACIJW ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB ADQXQ ADULT AE3 AE6 AEETU AENEX AEUPB AEXZC AFBFQ AFDTB AFFNX AFUWQ AGINI AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI ANHSF AOHHW AOQMC AQVQM BOYCO BQLVK BS7 BYPQX C45 CGR CS3 CUY CVF DCCCD DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HGD HLJTE HQ3 HTVGU HZ~ IKREB IKYAY IN~ IPNFZ IPSME JAAYA JBMMH JENOY JF9 JG8 JHFFW JK3 JK8 JKQEH JLS JLXEF JPM JSG JST K8S KD2 L-C N9A NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA OLG OLH OLU OLY OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S SA0 T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YCJ YOC ZFV ZGI ZZMQN 7X8 AAFWJ ABPXF ADKSD ADSXY |
| ID | FETCH-LOGICAL-c4116-cffccbb6f3ab1ff3f9f771e68d2d9c8855b2b878897310d286a5c5aa6a9fc6152 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 120 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000502323200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1531-5487 |
| IngestDate | Sat Sep 27 18:59:46 EDT 2025 Thu Apr 03 07:03:51 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4116-cffccbb6f3ab1ff3f9f771e68d2d9c8855b2b878897310d286a5c5aa6a9fc6152 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 31609860 |
| PQID | 2305797503 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2305797503 pubmed_primary_31609860 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-00 20200101 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Epidemiology (Cambridge, Mass.) |
| PublicationTitleAlternate | Epidemiology |
| PublicationYear | 2020 |
| SSID | ssj0017315 |
| Score | 2.613922 |
| SecondaryResourceType | review_article |
| Snippet | The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 43 |
| SubjectTerms | Case-Control Studies Humans Treatment Outcome Vaccines |
| Title | The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31609860 https://www.proquest.com/docview/2305797503 |
| Volume | 31 |
| WOSCitedRecordID | wos000502323200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JSgNBEG3UeBDEfYkbLXhtnLUXLxI0wYMJAY3kFqo38TKjTvT77WWiJ0FwDnObhZqqmup6Xe8hdGFZkVhdlgQKaUihjCBCUkoAEg0AliodBoXv2WjEp1MxbhtuTbutcpETQ6LWtfI98ktXKpdMeNTt-vWNeNUoj662EhrLqJO7UsZ7NZv-oAgsKhi4oE6Jr8wXo3OCXfZv-5G6sD1cyNPfi8zwsxls_vc1t9BGW2biXvSLbbRkqh20Hnt0OI4e7SLrfARPGoNrix_dI0hlngMPOL6JG9gbPK9xjPp3_ATKg_A48h23SfIK9_DDNxk0jkiDv98wKFOHnv0emgz6jzd3pNVdIKpwZiDKWqWkpDYHmVqbW2EZSw3lOtNCcV6WMpPcrZ297FWiM06hVCUABWGVq5CyfbRS1ZU5RDhnGlJwkQ4mKVLOpdGiAOlJZXKTaNtF5wszzpxfe7ACKlN_NLMfQ3bRQfwWs9dIwDHLU5oITpOjP1x9jNYyv0QOXZMT1LEuqs0pWlWf85fm_Sw4jDuPxsMv8dzLhQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Use+of+Test-negative+Controls+to+Monitor+Vaccine+Effectiveness%3A+A+Systematic+Review+of+Methodology&rft.jtitle=Epidemiology+%28Cambridge%2C+Mass.%29&rft.au=Chua%2C+Huiying&rft.au=Feng%2C+Shuo&rft.au=Lewnard%2C+Joseph+A&rft.au=Sullivan%2C+Sheena+G&rft.date=2020-01-01&rft.issn=1531-5487&rft.eissn=1531-5487&rft.volume=31&rft.issue=1&rft.spage=43&rft_id=info:doi/10.1097%2FEDE.0000000000001116&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1531-5487&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1531-5487&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1531-5487&client=summon |